HC Wainwright Analysts Reduce Earnings Estimates for UNCY

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Stock analysts at HC Wainwright cut their Q3 2026 EPS estimates for Unicycive Therapeutics in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.40) per share for the quarter, down from their previous forecast of ($0.31). HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($1.43) EPS, Q1 2027 earnings at ($0.31) EPS, Q2 2027 earnings at ($0.32) EPS, Q3 2027 earnings at ($0.27) EPS, Q4 2027 earnings at ($0.15) EPS, FY2027 earnings at ($1.05) EPS, FY2028 earnings at $1.98 EPS, FY2029 earnings at $3.08 EPS and FY2030 earnings at $3.11 EPS.

Several other research firms have also commented on UNCY. Zacks Research lowered shares of Unicycive Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 21st. Benchmark dropped their price objective on shares of Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating on the stock in a research note on Wednesday, July 1st. Guggenheim reissued a “buy” rating and issued a $25.00 target price (down from $37.00) on shares of Unicycive Therapeutics in a report on Thursday. Wall Street Zen upgraded Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, B. Riley Financial reaffirmed a “buy” rating and set a $20.00 target price (down from $22.00) on shares of Unicycive Therapeutics in a report on Wednesday, August 12th. Five investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $18.25.

Unicycive Therapeutics Trading Up 1.1%

Shares of UNCY opened at $5.57 on Monday. The firm has a market cap of $155.12 million, a price-to-earnings ratio of -3.18 and a beta of 1.79. The stock has a 50 day moving average of $5.92 and a 200-day moving average of $6.63. Unicycive Therapeutics has a 52 week low of $3.71 and a 52 week high of $8.74.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.41.

Hedge Funds Weigh In On Unicycive Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP bought a new position in shares of Unicycive Therapeutics during the first quarter worth about $940,000. Seven Fleet Capital Management LP acquired a new position in Unicycive Therapeutics during the 1st quarter valued at about $367,000. Geode Capital Management LLC boosted its stake in Unicycive Therapeutics by 36.2% during the 4th quarter. Geode Capital Management LLC now owns 171,290 shares of the company’s stock valued at $989,000 after purchasing an additional 45,563 shares during the period. Squarepoint Ops LLC acquired a new position in Unicycive Therapeutics during the 3rd quarter valued at about $512,000. Finally, OMERS ADMINISTRATION Corp bought a new position in Unicycive Therapeutics in the 4th quarter worth about $451,000. Institutional investors and hedge funds own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.